Education
About Us
Working with TipRanks
Follow Us
AstraZeneca (AZN)
:AZN
AZN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$61.24 - $82.41
Previous CloseN/A
Volume1.80M
Average Volume (3M)3.56M
Market Cap
$240.73B
Enterprise Value$243.71B
Total Cash (Recent Filing)$7.11B
Total Debt (Recent Filing)$32.84B
Price to Earnings (P/E)29.1
Beta0.29
Next Earnings
Nov 06, 2025EPS Estimate
1.15Last Dividend Ex-Date
Aug 08, 2025Dividend Yield2.01%
Share Statistics
EPS (TTM)1.08
Shares Outstanding3,101,386,000
10 Day Avg. Volume3,166,250
30 Day Avg. Volume3,557,805
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)4.98
Price to Sales (P/S)3.76
P/FCF Ratio27.92
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue5.68
Enterprise Value/Gross Profit7.04
Enterprise Value/Ebitda18.07
Forecast
1Y Price Target
$92.33Price Target Upside19.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Company GrowthManagement remains confident in their $80bn target for 2030, highlighting a combined >$10bn opportunity from readouts across 2025.
Market OpportunityAn increased probability of success for baxdrostat has been reflected in models, projecting significant future revenue.
Trial ResultsBaxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure compared with placebo.
Bears Say
Clinical Trial ChallengesThe clinical program evaluating anselamimab did not achieve statistical significance in the overall population for the primary endpoint.
Product PerformancePerformance across non-oncology products were mixed, with some products below consensus.
AstraZeneca News
AZN FAQ
What was AstraZeneca’s price range in the past 12 months?
AstraZeneca lowest stock price was $61.24 and its highest was $82.41 in the past 12 months.
What is AstraZeneca’s market cap?
AstraZeneca’s market cap is $240.73B.
When is AstraZeneca’s upcoming earnings report date?
AstraZeneca’s upcoming earnings report date is Nov 06, 2025 which is in 49 days.
How were AstraZeneca’s earnings last quarter?
AstraZeneca released its earnings results on Jul 29, 2025. The company reported $1.085 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.005.
Is AstraZeneca overvalued?
According to Wall Street analysts AstraZeneca’s price is currently Undervalued.
Does AstraZeneca pay dividends?
AstraZeneca pays a Semiannually dividend of $0.515 which represents an annual dividend yield of 2.01%. See more information on AstraZeneca dividends here
What is AstraZeneca’s EPS estimate?
AstraZeneca’s EPS estimate is 1.15.
How many shares outstanding does AstraZeneca have?
AstraZeneca has 3,101,386,000 shares outstanding.
What happened to AstraZeneca’s price movement after its last earnings report?
AstraZeneca reported an EPS of $1.085 in its last earnings report, beating expectations of $1.08. Following the earnings report the stock price went up 3%.
Which hedge fund is a major shareholder of AstraZeneca?
Currently, no hedge funds are holding shares in AZN
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$92.33 (19.04% Upside)
$92.33 (19.04% Upside)
Blogger Sentiment
Bullish
AZN Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.18%
12-Months-Change
Fundamentals
Return on Equity
19.76%
Trailing 12-Months
Asset Growth
7.75%
Trailing 12-Months
Company Description
AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AZN Company Deck
AZN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
AstraZeneca demonstrated strong financial performance and significant pipeline advancements, particularly in oncology and biopharmaceuticals. However, challenges remain with Medicare Part D redesign, biosimilar competition, and specific pipeline setbacks.View all AZN earnings summariesAZN Stock 12 Month Forecast
Average Price Target
$92.33
▲(19.04% Upside)
Technical Analysis
Ownership Overview
―
Insiders
5.54% Mutual Funds
6.15% Other Institutional Investors
87.36% Public Companies and Individual Investors